Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718466 · ClinicalTrials.gov registry record · Phase 3
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
A Phase 3 study of Recurrent or Progressive Glioblastoma, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05718466: Completed Phase 3 study of Recurrent or Progressive Glioblastoma, sponsored by Henry Ford Health System.
NCT05718466 is a Phase 3 study of Recurrent or Progressive Glioblastoma that has completed, run by Henry Ford Health System. The registered enrollment target is 35 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05718466, a Phase 3 study of Recurrent or Progressive Glioblastoma, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Chemotherapy
- RADIATION Fractionated radiosurgery
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT05718466 record still lists
NCT05718466 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Recurrent or Progressive Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT05718466 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05718466 about?
NCT05718466 is a clinical study titled "Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy". This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.
What is the current status of trial NCT05718466?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2010-11. Estimated completion is 2016-12.
What conditions does trial NCT05718466 study?
This clinical trial studies the following conditions: Recurrent or Progressive Glioblastoma.
What interventions are being tested in trial NCT05718466?
The interventions under investigation include: Bevacizumab (DRUG), Chemotherapy (DRUG), Fractionated radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT05718466?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718466 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05718466's enrollment target sits among peer trials
35 1903rd of 2000 higher than 96 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia